Nomura Research Institute, Ltd.
Nomura Research Institute, Ltd. Fundamental Analysis
Nomura Research Institute, Ltd. (NURAF) shows weak financial fundamentals with a PE ratio of 146.67, profit margin of 1.86%, and ROE of 3.28%. The company generates $821.2B in annual revenue with moderate year-over-year growth of 3.84%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 47.2/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze NURAF's fundamental strength across five key dimensions:
Efficiency Score
WeakNURAF struggles to generate sufficient returns from assets.
Valuation Score
ModerateNURAF shows balanced valuation metrics.
Growth Score
ModerateNURAF shows steady but slowing expansion.
Financial Health Score
ExcellentNURAF maintains a strong and stable balance sheet.
Profitability Score
WeakNURAF struggles to sustain strong margins.
Key Financial Metrics
Is NURAF Expensive or Cheap?
P/E Ratio
NURAF trades at 146.67 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, NURAF's PEG of -0.01 indicates potential undervaluation.
Price to Book
The market values Nomura Research Institute, Ltd. at 5.12 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 10.20 times EBITDA. This signals the market has high growth expectations.
How Well Does NURAF Make Money?
Net Profit Margin
For every $100 in sales, Nomura Research Institute, Ltd. keeps $1.86 as profit after all expenses.
Operating Margin
Core operations generate 19.03 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.28 in profit for every $100 of shareholder equity.
ROA
Nomura Research Institute, Ltd. generates $1.58 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Nomura Research Institute, Ltd. produces operating cash flow of $148.65B, showing steady but balanced cash generation.
Free Cash Flow
Nomura Research Institute, Ltd. generates strong free cash flow of $142.76B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $248.53 in free cash annually.
FCF Yield
NURAF converts 5.91% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
146.67
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.12
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.74
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.54
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.84
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.23
vs 25 benchmark
How NURAF Stacks Against Its Sector Peers
| Metric | NURAF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 146.67 | 37.24 | Worse (Expensive) |
| ROE | 3.28% | 986.00% | Weak |
| Net Margin | 1.86% | 5872992870.00% | Weak |
| Debt/Equity | 0.54 | 0.34 | Weak (High Leverage) |
| Current Ratio | 1.84 | 5.14 | Neutral |
| ROA | 1.58% | -293612.00% (disorted) | Weak |
NURAF outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Nomura Research Institute, Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
59.82%
Industry Style: Growth, Innovation, High Beta
High GrowthEPS CAGR
49.58%
Industry Style: Growth, Innovation, High Beta
High GrowthFCF CAGR
27.52%
Industry Style: Growth, Innovation, High Beta
High Growth